Evidence map›Paper›PMID 39353739›Full record

ArticleLife science alliance2024

PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.

Sylvie Gazzeri, Nadiia Zubchuk, Elodie Montaudon, Fariba Nemati, Sarah Huot-Marchand, Giulia Berardi, Amelie Pucciarelli, Yassir Dib, Dylan Nerini, Christiane Oddou and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sylvie GazzeriUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France sylvie.gazzeri@univ-grenoble-alpes.fr.ORCID 0000-0001-5817-1839
Nadiia ZubchukUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.ORCID 0009-0007-7282-2133
Elodie MontaudonLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France.
Fariba NematiLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France.
Sarah Huot-MarchandUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
Giulia BerardiDepartment of Pneumology and Physiology, Grenoble-Alpes University Hospital, Grenoble, France.
Amelie PucciarelliUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
Yassir DibUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
Dylan NeriniUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
Christiane OddouUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Epigenetics, Immunity, Metabolism, Cell Signaling and Cancer, Institute for Advanced Biosciences, Grenoble, France.
Mylène PezetUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Platform MicroCell, Institute for Advanced Biosciences, Grenoble, France.ORCID 0000-0002-4365-7454
Laurence David-BoudetDepartment of Cytology and Pathology, Grenoble-Alpes University Hospital, Grenoble, France.
Camille ArdinUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
Florence de FraipontUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.ORCID 0000-0001-9594-6584
Antonio MaraverInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194-ICM-Université de Montpellier, Montpellier, France.
Nicolas GirardInstitut du Thorax Curie-Montsouris, Institut Curie, Paris, France.
Didier DecaudinLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France.
Anne-Claire ToffartUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
Beatrice EyminUniversity Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France beatrice.eymin@univ-grenoble-alpes.fr.ORCID 0000-0002-7311-3810

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite initial high response rates to first-line EGFR TKI, all non-small-cell lung cancer (NSCLC) with EGFR-activating mutation will ultimately develop resistance to treatment. Identification of resistance mechanisms is critical to adapt treatment and improve patient outcomes. Here, we show that a

Indexed as

CalcineurinCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmErbB ReceptorsLung NeoplasmsMAP Kinase Signaling SystemProtein Kinase InhibitorsAnimalsApoptosisCell Line, TumorFemaleHumansMiceMice, NudeMutationXenograft Model Antitumor AssaysCalcineurinEGFR protein, humanErbB ReceptorsPPP3CB protein, humanProtein Kinase Inhibitors

Identifiers

PMID39353739
PMCPMC11447527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.